Lundbeckfonden Emerge
VC Fund
Copenhagen, Denmark
Lundbeckfonden Emerge is a VC fund in Copenhagen focused on Biotechnology and Health Care. Lundbeckfonden Emerge seeks to identify and initiate commercial development of scientific opportunities which it considers from its analysis have high commercial potential. The main objective is to turn scientific discoveries and early stage opportunities into commercial ventures with a maturity that allows for full venture financing.Lundbeckfonden Emerge not only offers limited financing for selected cases but also offers seasoned advice or direct participation in new ventures, as part of its unique model to optimize the outcome of the venture to the benefit of all stakeholders. Lundbeckfonden Emerge will seek to develop select projects together with founders and will take on an active role from mentoring to active project management, as is considered optimal for the outcome of the specific project. In this way, Lundbeckfonden Emerge is not a replication of traditional seed funds, but rather a unique way of using research funds to get to commercially viable projects.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Lundbeckfonden Emerge invests in
Stages Lundbeckfonden Emerge invests in
Countries Lundbeckfonden Emerge invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christian E. Elling
|
|||
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 2 (25%)
- Therapeutics 2 (25%)
- Pharmaceutical 2 (25%)
- Medical 1 (13%)
Stage
- Series A 3 (38%)
- Series B 2 (25%)
- Funding Round 1 (13%)
- Debt Financing 1 (13%)
- Venture - Series Unknown 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Christian E. Elling
Managing Partner, Lundbeckfonden BioCapital
|
Managing Partner, Lundbeckfonden BioCapital | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NMD Pharma
|
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $81.4M / Series B / Nov 15, 2023 | |
|
NMD Pharma
|
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $39.7M / Venture - Series Unknown / Feb 15, 2022 | |
Cytoki Pharma
|
Cytoki Pharma is a biotechnology company that specializes in developing novel medicines for diseases with a significant unmet medical need with a focus on serious diseases caused by epithelial injury. | $45M / Series A / May 04, 2021 | |
IO Biotech
|
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proventrack record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase. | $154.5M / Series B / Jan 13, 2021 | |
AFYX Therapeutics
|
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinningtechnology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities. | $13M / Debt Financing / Jun 24, 2019 | |
|
NMD Pharma
|
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $41.7M / Series A / Mar 23, 2018 | |
|
AFYX Therapeutics
|
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinningtechnology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities. | $17.8M / Series A / May 09, 2017 | |
|
NMD Pharma
|
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $3M / Jul 01, 2016 |
Co-Investors
Novo Holdings
7 deals together
Jeito Capital
4 deals together
Inkef
3 deals together
Roche Venture Fund
3 deals together
Avoro Capital Advisors
1 deal together
CAPNOVA
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lundbeckfonden Emerge invest in?
Lundbeckfonden Emerge invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lundbeckfonden Emerge?
Public channels for Lundbeckfonden Emerge include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lundbeckfonden Emerge?
The team at Lundbeckfonden Emerge includes Christian E. Elling (Managing Partner, Lundbeckfonden BioCapital). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
